INCREASING M&A IN SME BIOPHARMAS IS INEVITABLE in the face of scarce resources and a high failure rate. In many cases, the core technology of a struggling company has valuable uses, but in the struggle for capital, with an oversupply of young preclinical companies, the entire portfolio can easily be lost. A better strategy is to consider merging with a competitor so that the technology can retain value.
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022